BGC
NVO

Beutel, Goodman & Co’s Novo Nordisk NVO Stock Holding History

Beutel, Goodman & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.12M Sell
57,713
-2,300
-4% -$109K 0.01% 98
2025
Q4 		$3.05M Sell
60,013
-3,425
-5% -$175K 0.02% 84
2025
Q3 		$3.52M Sell
63,438
-9,080
-13% -$531K 0.02% 81
2025
Q2 		$5M Sell
72,518
-6,645
-8% -$452K 0.03% 77
2025
Q1 		$5.5M Buy
+79,163
New +$6.54M 0.03% 78

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Beutel, Goodman & Co's NVO Position: Q1 2026 in Review

Beutel, Goodman & Co reduced its Novo Nordisk (NVO) stake by 3.8% in Q1 2026, selling an estimated $109K and leaving 57,713 shares worth $2.12M. The position accounts for 0.01% of the portfolio, ranked #98.

Beutel, Goodman & Co first reported a position in NVO in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.5M in Q1 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Beutel, Goodman & Co held 57,713 shares of Novo Nordisk worth $2.12M as of Q1 2026.
  • Beutel, Goodman & Co sold 2,300 Novo Nordisk shares in Q1 2026, an estimated $109K.
  • Novo Nordisk made up 0.01% of Beutel, Goodman & Co's portfolio in Q1 2026, its #98 holding.
  • Beutel, Goodman & Co first reported a position in Novo Nordisk in Q1 2025 and has held it in 5 quarters since.
  • Beutel, Goodman & Co's Novo Nordisk position peaked at $5.5M in Q1 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Beutel, Goodman & Co's 13F filing for Q1 2026, filed 15 May 2026.